Top Markets
Coin of the day
Nuformix plc Nuformix plc

Nuformix plc

NFX
주식 순위 #41014
Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes... Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes in developing therapies for fibrotic diseases and cancer, primarily through the innovative strategy of drug repurposing. Its current development portfolio includes NXP001, which has advanced beyond Phase 1 trials for application in oncology supportive care. Additionally, the company is progressing NXP004, a novel variant of Olaparib, currently in its intellectual property generation stage for oncological indications, and NXP002, which is undergoing pre-clinical evaluation for the treatment of idiopathic pulmonary fibrosis. Nuformix also holds an option agreement with Oxilio Ltd. concerning NXP001 for its oncology applications. Established in 2008, the company maintains its operational base in London.
주가
$0.00185055
시가총액
$48.29K
변동 (1일)
-3.55%
변동 (1년)
30.31%
국가
GB
거래 Nuformix plc (NFX)

카테고리

Nuformix plc (NFX)의 수익
Mar 2026 기준 수익 TTM: $-857.89K
Nuformix plc의 최신 재무 보고서에 따르면 회사의 현재 수익은 $-857.89K입니다. 2024년에 회사는 $-4.88M의 수익을 올렸으며 이는 2023년의 수익 $-754.56K과 감소입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Nuformix plc의 수익 기록 (2014 ~ 2026)
연말 수익
연도 수익 변화
2026 (TTM) $-857.89K -3.39%
2025 $-888.01K -81.80%
2024 $-4.88M 546.72%
2023 $-754.56K -54.82%
2022 $-1.67M -11.94%
2021 $-1.90M 64.37%
2020 $-1.15M -51.92%
2019 $-2.40M -12.87%
2018 $-2.75M 220.48%
2017 $-859.40K 70.68%
2016 $-503.51K -206.04%
2014 $474.83K 0.00%
유사 기업 또는 경쟁사의 수익
회사 수익 수익 차이 국가
$5.27B -614,967.33%
US
$-3.09B 359,735.34%
US
$-4.02B 468,046.88%
AU
$1.95B -227,477.01%
NL
- -
CH